Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 25 clinical trials
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer

This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may

  • 10 views
  • 08 Nov, 2021
  • 3 locations
CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab

This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers

oxaliplatin
ct scan
leucovorin
BRAF
adenocarcinoma
  • 0 views
  • 01 Dec, 2021
  • 3 locations
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

This is a phase II, open-label, non-randomized study in subjects with histologically confirmed diagnosis of left-sided RAS WT advanced adenocarcinoma of the colon or rectum who have not received prior systemic therapy for metastatic disease.

oxaliplatin
neutrophil count
systemic chemotherapy
adenocarcinoma of colon
panitumumab
  • 8 views
  • 04 Oct, 2022
  • 8 locations
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as

  • 20 views
  • 04 Oct, 2022
  • 1 location
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE)

The purpose of this study is to assess the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence

folfox regimen
ki-ras
neutrophil count
folfiri regimen
panitumumab
  • 5 views
  • 01 Feb, 2022
  • 1 location
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)

This phase II trial how well regorafenib and anti-EGFR therapy (cetuximab or panitumumab) works for the treatment of patients with colorectal cancer that cannot be removed by surgery

  • 0 views
  • 22 Sep, 2022
  • 15 locations
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

This phase I/II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride (phase I only) in treating

ct scan
ki-ras
neutrophil count
panitumumab
solid tumour
  • 36 views
  • 23 Apr, 2022
  • 1 location
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

commonly used to treat CRC (leucovorin, oxaliplatin, irinotecan, bevacizumab, cetuximab and panitumumab). The primary objective is to identify a recommended dose and schedule for NUC-3373 when combined

oxaliplatin
panitumumab
bevacizumab
measurable disease
fluorouracil
  • 17 views
  • 22 Mar, 2022
  • 6 locations
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR)

or not with the targeted therapies (anti-EGFR (panitumumab), anti-VEGF (bevacizumab)). In this patient population, special attention was paid to intensified treatment regimens in order to improve

oxaliplatin
vascular endothelial growth factor
ki-ras
liver metastasis
systemic chemotherapy
  • 1 views
  • 19 Apr, 2022
  • 82 locations
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.

EGFR targeted antibodies such as Cetuximab and Panitumumab . Detection of such mutations has been done on tissue biopsies with the disadvantage of this being an invasive procedure, and data suggesting

  • 0 views
  • 09 Mar, 2021
  • 1 location